Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sarcoidosis Clear all
Completed No phase listed Observational

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT03746847
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Gallium-68 DOTATATE
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 19, 2026, 7:18 PM EDT
Recruiting Phase 2 Interventional

Rilonacept in Subjects With Cardiac Sarcoidosis

NCT06660732
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Rilonacept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 19, 2026, 7:18 PM EDT
Not listed No phase listed Observational

Monitoring and Evaluation Study of Project ECHO for ILD

NCT05455437
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 19, 2026, 7:18 PM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 19, 2026, 7:18 PM EDT
Not listed Phase 4 Interventional

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558
View directory record Official record
Conditions
Sarcoidosis
Interventions
Riociguat, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Not applicable Interventional

Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis

NCT00609687
View directory record Official record
Conditions
Sarcoidosis-associated Ocular Inflammation
Interventions
Diagnostic Vitrectomy
Procedure
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

NCT02039687
View directory record Official record
Conditions
Neuropathy of Sarcoidosis
Interventions
ARA 290, Placebo
Drug · Other
Lead sponsor
Araim Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional

A Study of Adalimumab to Treat Sarcoidosis of the Skin

NCT00274352
View directory record Official record
Conditions
Sarcoidosis
Interventions
adalimumab
Drug
Lead sponsor
Pariser, Robert J., M.D.
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational

Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases

NCT00366509
View directory record Official record
Conditions
Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis, Asthma, Sarcoidosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational

CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases

NCT06907953
View directory record Official record
Conditions
Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
Interventions
Observational - no intervention
Other
Lead sponsor
4YouandMe
Other
Eligibility
14 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Lung Microbiome in Sarcoidosis

NCT02520323
View directory record Official record
Conditions
Sarcoidosis
Interventions
Blood draw, Bronchoscopy, Questionnaires
Other · Procedure · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT06169397
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
XTMAB-16
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 19, 2026, 7:18 PM EDT
Not listed No phase listed Observational

Registry for Advanced Sarcodiosis

NCT03769987
View directory record Official record
Conditions
Sarcoidosis
Interventions
observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational

Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis

NCT01013311
View directory record Official record
Conditions
Sarcoidosis of the Heart, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Proteins in Disease and Health

NCT00100204
View directory record Official record
Conditions
Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246
View directory record Official record
Conditions
Sarcoidosis
Interventions
Adalimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 19, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

NCT05351554
View directory record Official record
Conditions
Sarcoidosis, Cardiac
Interventions
Namilumab
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 19, 2026, 7:18 PM EDT
Completed No phase listed Observational

Routine Cardiac Screening in Sarcoidosis Patients

NCT03902223
View directory record Official record
Conditions
Sarcoidosis, Cardiac Sarcoidosis, Boeck's Disease, Besnier-Boeck Disease
Interventions
Enhanced Screening Protocol for Cardiac Sarcoidosis., Routine Screening for Suspected Cardiac Sarcoidosis
Diagnostic Test
Lead sponsor
Foundation for Sarcoidosis Research
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 7:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039
View directory record Official record
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin to Treat Pulmonary Sarcoidosis

NCT00279708
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 19, 2026, 7:18 PM EDT
Not listed No phase listed Observational

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

NCT01467791
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 19, 2026, 7:18 PM EDT